Montelukast

Sarcoma

University of South FloridaSmall moleculeEarly Phase 1Active

C

36/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 73/ 100

Competitive context

109 Active assets in the Sarcoma cohort.

Asset / Sponsor	Phase	Rating
ETOPOSIDE National Cancer Institute (NCI)	Phase 2	BB
Cyclophosphamide Essen Biotech	Phase 2	BB
Ifosfamide City of Hope Medical Center	Phase 3	BB
Inno-206 City of Hope Medical Center	Phase 3	BB
Carboplatin OHSU Knight Cancer Institute	Phase 2	BB

View all 50 →

Same molecule, other indications

Montelukast is also rated in:

metabolic dysfunction-associated steatohepatitisDormant

BBB

Indicative ·

73 / 100

asthmaDormant

BBB

Indicative ·

73 / 100

Fabry diseaseDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.